13.18
Aşı Üretimi
Aşı üretimi, güvenli ve etkili bir immünolojik ürün üretmek için üst ve aşağı akış süreçlerinin ardışıklığını içerir. Başlangıçta, antijenik materyal…
Aşı üretimi, virüs veya bakteri gibi patojenlerin yetiştirilerek antijen üretmesiyle başlar.
Özellikle tüm virüs aşıları için memeli hücreleri gibi konak hücreler biyoreaktörlerde yetiştirilir ve virüsle enfekte edilir.
Virüs, konak hücrelerin içinde çoğalır ve ardından lizize edilip viral parçacıklar serbest bırakılır.
Virüs içeren karışım, hücre kalıntılarını temizlemek için arındırılır ve ardından arıtılır.
Saflaştırıldıktan sonra, virüs zayıflatılmış bir formda tutulabilir veya aşı türüne bağlı olarak ısı, formaldehit gibi kimyasallar veya radyasyonla öldürülerek inaktive edilebilir.
Bakteriyel aşılar için, bakteriler besin açısından zengin ortamlarda kontrollü koşullarda kültürlenir.
Hücreler daha sonra toplanır ve santrifüjle ayrılır.
Tam hücreli bakteriyel aşılar için hücreler ısı veya kimyasallarla toplanır ve inaktive edilir.
Toksoid aşılar için, süpernatantta salgılanan toksinler toplanır ve inaktive edilir.
Ortaya çıkan antijenler, adjuvanlar ve stabilizatörlerle formüle edilip nihai aşı üretilir.
View the full transcript and gain access to JoVE Core videos
Q1: How are viral vaccines produced from host cells?
Mammalian host cells are grown in bioreactors and infected with the target virus. The virus replicates inside these cells, which are then lysed to release viral particles. The resulting mixture is clarified to remove cell debris and subsequently purified to isolate the virus for vaccine formulation.
Q2: What methods are used to inactivate viruses in vaccine production?
Purified viruses can be inactivated through chemical treatment with formaldehyde or beta-propiolactone, or by exposure to heat or radiation. These inactivation methods render the virus non-infectious while preserving its antigenicity, ensuring the virus remains immunogenic and safe for use in inactivated vaccines.
Q3: How are bacterial vaccines produced differently from viral vaccines?
Bacterial strains are cultured in nutrient-rich media under controlled conditions, then harvested using centrifugation or filtration. Depending on the vaccine type, bacterial cells can be heat-inactivated for killed vaccines, or toxins can be isolated and inactivated with formaldehyde to create toxoid vaccines.
Q4: What role do adjuvants and stabilizers play in vaccine formulation?
After antigen purification, adjuvants are combined with the antigen to enhance the immune response. Stabilizers maintain vaccine potency during storage, while preservatives prevent microbial contamination. The formulation undergoes sterile filtration before being filled into vials or syringes for distribution to patients.
Q5: What quality control tests ensure vaccine safety and efficacy?
Rigorous quality control protocols include sterility testing, potency assays, identity verification, and purity analysis using methods like ELISA, SDS-PAGE, and HPLC. Each batch is tested to comply with regulatory standards before packaging and distribution, ensuring safety and effectiveness for patients.
Q6: Why is cold chain logistics important in vaccine production?
Vaccines are packaged under aseptic conditions in unit doses or multi-dose containers with appropriate labeling including batch numbers and expiration dates. Cold chain logistics are implemented to preserve vaccine stability from production through administration, maintaining potency and safety throughout distribution.
Q7: How does downstream processing contribute to vaccine purity?
Downstream processing involves purification steps such as chromatography and ultrafiltration to isolate viral or bacterial antigens from culture mixtures. These processes remove contaminants and cellular debris, ensuring the final antigen preparation is pure and suitable for formulation into the finished vaccine product.